Printer Friendly

Low plasma CoQ10 predicts mortality in heart failure patients.

A recent issue of the Journal of the American College of Cardiology features a study showing that coenzyme Q10 (CoQ10) levels are an independent predictor of survival in chronic heart failure patients. (1)


The study included 236 heart failure patients with a median age of 77 years upon admission to Christchurch Hospital in New Zealand. Plasma samples were analyzed for CoQ10 and other factors. Participants were followed for a period of up to 5.75 years, during which 76 deaths occurred.

Over the follow-up period, 39% of the participants who had CoQ10 levels lower than 0.63 micrograms per milliliter died, compared with only 22% of those whose levels were higher. This study also indicated that those with lower CoQ10 were 67% more likely to die.

"Our findings in a clearly defined, prospectively studied group that CoQ10 depletion is associated with worse outcomes in chronic heart failure give further support to the rationale of the intervention studies that have already been initiated," the authors concluded.

Life Extension has conducted numerous CoQ10 blood level studies in humans. Our findings reveal that a CoQ10 blood reading of 0.63 micrograms per milliliter used in this study to help predict mortality risk is common in aging people who don't supplement. In response to supplementation with the ubiquinol form of CoQ10, blood levels typically increase to 2.00 to 3.00 micrograms per milliliter, a range that appears to confer protection against a host of degenerative disorders.

As reported exactly one year ago in Life Extension magazine, a significant clinical benefit in heart failure patients requires a plasma CoQ10 level of around 4.00 micrograms per milliliter. (2-4) In severe heart failure patients, the only way these higher levels can be obtained appears to be with ubiquinol--not conventional ubiquinone CoQ10 supplements.


(1.) Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10. An independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008 Oct 28;52:1435-41.

(2.) Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-84.

(3.) Langsjoen PH, Littarru GP, Silver MA. Role of concomitant coenzyme Q10 with statins for patients with hyperlipidemia. Curr Topics Nutr Res.2005;3 (3):149-58.

(4.) Langsjoen PH, Langsjoen AM. Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischaemia. Asia Pacific Heart J. 1998;7(3):160-8.

COPYRIGHT 2009 LE Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:IN THE NEWS; coenzyme Q10
Author:Faloon, William
Publication:Life Extension
Geographic Code:1USA
Date:Feb 1, 2009
Previous Article:The cholesterol controversy.
Next Article:Vitamin K may reduce insulin resistance in older men.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |